Application of CDK4/6 Inhibitors in Premenopausal Women with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: a Real-World Experience

被引：0

作者：

Kurbacher, Christian M. ^{[1
]}

Fischer, Lotta Ada ^{[2
]}

Heinrich, Georg ^{[3
]}

Herz, Susanne ^{[1
]}

Schott, Alexander ^{[1
]}

Kurbacher, A. Tabea ^{[1
]}

Kurbacher, Jutta Anna ^{[4
]}

Rudlowski, Christian ^{[5
]}

Warm, Mathias R. ^{[2
]}

机构：

[1] Gynakol Zentrum Bonn Friedenspl, Gynakol Schwerpunkt Gynakol Onkol 1, Bonn, Germany

[2] Stadt Klinikum Holweide, Brustzentrum, Cologne, Germany

[3] Praxis Gynakol Onkol, Furstenwalde, Germany

[4] Gynakol Zentrum Bonn Friedenspl, Gynakol Allgemeine Gynakol & Geburtshilfe 2, Bonn, Germany

[5] Evangel Krankenhaus Bergisch Gladbach, Frauenklin, Bergisch Gladbach, Germany

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2020年 / 43卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

552

引用

页码：19 / 19

页数：1

共 50 条

[41] Mechanisms of Resistance to CDK4/6 Blockade in Advanced Hormone Receptor-positive, HER2-negative Breast Cancer and Emerging Therapeutic Opportunities
Lloyd, Maxwell R.
Spring, Laura M.
Bardia, Aditya
Wander, Seth A.
CLINICAL CANCER RESEARCH, 2022, 28 (05) : 821 - 830
[42] Abemaciclib and endocrine therapy for hormone receptor-positive, HER2-negative advanced breast cancer: A real-world UK multicentre experience
Battisti, Nicolo Matteo Luca
Morrison, Laura
Nash, Tamsin
Senthivel, Nishanti
Kestenbaum, Samantha
Begum, Parvin
Obeid, Mariam
Hayhurst, William
Yang, Dorothy
Gafoor, Shafiah
Brown, Caroline
Rehman, Farah
Kenny, Laura
Hatcher, Olivia
Susan, Susan
Williams, Jennet
Brown, Anna
Rozati, Hamoun
Alexandros, Alexandros
Sawyer, Elinor
Gousis, Charalampos
Karapanagiotou, Eleni
Rigg, Anna
Rapti, Kleopatra
Roylance, Rebecca
Beresford, Mark
Gee, Abigail L.
Konstantis, Apostolos
King, Judy
Nathan, Mark
Spurrell, Emma
Pearce, Mark
Bradwell, Dane
Denton, Arshi
Swain, Kate
McGrath, Sophie
Allen, Mark
Ring, Alistair
Johnston, Stephen
Raja, Fharat
CANCER RESEARCH, 2022, 82 (04)
[43] Optimizing care for younger women with hormone receptor-positive, HER2-negative metastatic breast cancer
de Boer, Richard
Hui, Rina
Lim, Elgene
Yeo, Belinda
Zdenkowski, Nicholas
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 : 3 - 14
[44] Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor-Positive (HR+)/HER2-Negative Metastatic Breast Cancer
Davis, Andrew A.
Luo, Jingqin
Zheng, Tiantian
Dai, Chao
Dong, Xiaoxi
Tan, Lu
Suresh, Rama
Ademuyiwa, Foluso O.
Rigden, Caron
Rearden, Timothy P.
Clifton, Katherine
Weilbaecher, Katherine
Frith, Ashley
Tandra, Pavan K.
Summa, Tracy
Haas, Brittney
Thomas, Shana
Hernandez-Aya, Leonel F.
Peterson, Lindsay L.
Wang, Xiaohong
Luo, Shujun J.
Zhou, Kemin
Du, Pan
Jia, Shidong
King, Bonnie L.
Krishnamurthy, Jairam
Ma, Cynthia X.
CLINICAL CANCER RESEARCH, 2023, 29 (09) : 1719 - 1729
[45] Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitors
Zattarin, Emma
Mariani, Luigi
Menichetti, Alice
Leporati, Rita
Provenzano, Leonardo
Ligorio, Francesca
Fuca, Giovanni
Lobefaro, Riccardo
Lalli, Luca
Vingiani, Andrea
Nichetti, Federico
Griguolo, Gaia
Sirico, Marianna
Bernocchi, Ottavia
Marra, Antonio
Corti, Chiara
Zagami, Paola
Agostinetto, Elisa
Jacobs, Flavia
Di Mauro, Pierluigi
Presti, Daniele
Sposetti, Caterina
Giorgi, Carlo Alberto
Guarneri, Valentina
Pedersini, Rebecca
Losurdo, Agnese
Generali, Daniele
Curigliano, Giuseppe
Pruneri, Giancarlo
de Braud, Filippo
Dieci, Maria Vittoria
Vernieri, Claudio
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
[46] Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitors
Zattarin, Emma
Mariani, Luigi
Menichetti, Alice
Leporati, Rita
Provenzano, Leonardo
Ligorio, Francesca
Fuca, Giovanni
Lobefaro, Riccardo
Lalli, Luca
Vingiani, Andrea
Nichetti, Federico
Griguolo, Gaia
Sirico, Marianna
Bernocchi, Ottavia
Marra, Antonio
Corti, Chiara
Zagami, Paola
Agostinetto, Elisa
Jacobs, Flavia
Di Mauro, Pierluigi
Presti, Daniele
Sposetti, Caterina
Giorgi, Carlo Alberto
Guarneri, Valentina
Pedersini, Rebecca
Losurdo, Agnese
Generali, Daniele
Curigliano, Giuseppe
Pruneri, Giancarlo
de Braud, Filippo
Dieci, Maria Vittoria
Vernieri, Claudio
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
[47] Hormone receptor-positive, HER2-negative metastatic breast cancer: redrawing the lines
Matutino, A.
Joy, A. A.
Brezden-Masley, C.
Chia, S.
Verma, S.
CURRENT ONCOLOGY, 2018, 25 : S131 - S141
[48] Comparative Overall Survival of CDK4/6 Inhibitors Plus Endocrine Therapy vs. Endocrine Therapy Alone for Hormone receptor-positive, HER2-negative metastatic breast cancer
Lin, Mingxi
Chen, Yang
Jin, Yizi
Hu, Xichun
Zhang, Jian
JOURNAL OF CANCER, 2020, 11 (24): : 7127 - 7136
[49] Real-World Experience with CDK4/6 Inhibitors for Metastatic HR+/HER2-Breast Cancer at a Single Cancer Center
Knudsen, Erik S.
Schultz, Emily
Hamilton, Deanna
Attwood, Kris
Edge, Stephen
O'Connor, Tracey
Levine, Ellis
Witkiewicz, Agnieszka K.
ONCOLOGIST, 2022, 27 (08): : 646 - 654
[50] Real-world experience with CDK4/6 inhibitors for metastatic HR+/HER2-breast cancer at a single cancer center
Milovic-Kovacevic, M.
Bobic, S.
Karaferic, A.
Pavlovic, L.
Matovic, M.
Poparic-Bandjur, B.
BREAST, 2023, 68 : S115 - S115

← 1 2 3 4 5 →